Xia, Yushan http://orcid.org/0000-0002-5946-7671
Wei, Xueying http://orcid.org/0000-0002-6353-2763
Gao, Peng http://orcid.org/0000-0002-6877-6388
Wang, Chenyuan http://orcid.org/0000-0003-0596-2949
de Jong, Anne http://orcid.org/0000-0002-7024-2334
Chen, Jonathan Hon Kwan http://orcid.org/0000-0002-7510-1696
Rodríguez-Sánchez, María José
Rodríguez-Nogales, Alba
Diez-Echave, Patricia
Gálvez, Julio
García, Federico http://orcid.org/0000-0001-7611-781X
Wu, Weihui
Kao, Richard Yi-Tsun
Li, Hongyan http://orcid.org/0000-0002-1158-5871
Cebrián, Rubén http://orcid.org/0000-0003-1575-1846
Kuipers, Oscar P. http://orcid.org/0000-0001-5596-7735
Sun, Hongzhe http://orcid.org/0000-0001-6697-6899
Funding for this research was provided by:
Research Grants Council, University Grants Committee (R7070-18, 17308921, SRFS2122-7S04)
China Scholarship Council (201906200035)
National Natural Science Foundation of China (32300155)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CP21/00113)
Article History
Received: 24 January 2024
Accepted: 8 August 2024
First Online: 18 September 2024
Competing interests
: O.P.K., Y.X. and R.C. are coinventors on a patent application associated with this work entitled ‘synergistic composition against <i>Pseudomonas aeruginosa</i>’, with reference number N2029436 (2021). O.P.K. is also cofounder and board member of the company Omnicin Therapeutics that is developing novel therapies against <i>P. aeruginosa</i>. The other authors declare no competing interests.